Andy Sassine - Net Worth and Insider Trading

Andy Sassine Net Worth

The estimated net worth of Andy Sassine is at least $10 Million dollars as of 2024-05-21. Andy Sassine is the CFO of Arcturus Therapeutics Holdings Inc and owns about 273,245 shares of Arcturus Therapeutics Holdings Inc (ARCT) stock worth over $8 Million. Andy Sassine is the Director of icad Inc and owns about 1,198,382 shares of icad Inc (ICAD) stock worth over $2 Million. Andy Sassine is also the Director of NeuroBo Pharmaceuticals Inc and owns about 23 shares of NeuroBo Pharmaceuticals Inc (NRBO) stock worth over $106. Details can be seen in Andy Sassine's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Andy Sassine has not made any transactions after 2022-02-08 and currently still holds the listed stock(s).

Transaction Summary of Andy Sassine

To

Andy Sassine Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Andy Sassine owns 6 companies in total, including icad Inc (ICAD) , Arcturus Therapeutics Holdings Inc (ARCT) , and NeuroBo Pharmaceuticals Inc (NRBO) among others .

Click here to see the complete history of Andy Sassine’s form 4 insider trades.

Insider Ownership Summary of Andy Sassine

Ticker Comapny Transaction Date Type of Owner
ICAD icad Inc 2022-02-08 director
ARCT Arcturus Therapeutics Holdings Inc 2020-06-10 Chief Financial Officer
NRBO NeuroBo Pharmaceuticals Inc 2017-03-10 director
2013-02-25 director
2013-09-20 director
2021-03-05 director

Andy Sassine Latest Holdings Summary

Andy Sassine currently owns a total of 3 stocks. Among these stocks, Andy Sassine owns 273,245 shares of Arcturus Therapeutics Holdings Inc (ARCT) as of June 10, 2020, with a value of $8 Million and a weighting of 80.92%. Andy Sassine owns 1,198,382 shares of icad Inc (ICAD) as of February 8, 2022, with a value of $2 Million and a weighting of 19.08%. Andy Sassine also owns 23 shares of NeuroBo Pharmaceuticals Inc (NRBO) as of March 10, 2017, with a value of $106 and a weighting of 0%.

Latest Holdings of Andy Sassine

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ARCT Arcturus Therapeutics Holdings Inc 2020-06-10 273,245 30.50 8,333,973
ICAD icad Inc 2022-02-08 1,198,382 1.64 1,965,346
NRBO NeuroBo Pharmaceuticals Inc 2017-03-10 23 4.60 106

Holding Weightings of Andy Sassine


Andy Sassine Form 4 Trading Tracker

According to the SEC Form 4 filings, Andy Sassine has made a total of 4 transactions in Arcturus Therapeutics Holdings Inc (ARCT) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Arcturus Therapeutics Holdings Inc is the acquisition of 5,000 shares on June 10, 2020, which cost Andy Sassine around $148,700.

According to the SEC Form 4 filings, Andy Sassine has made a total of 9 transactions in icad Inc (ICAD) over the past 5 years, including 0 buys and 9 sells. The most-recent trade in icad Inc is the sale of 20,000 shares on February 8, 2022, which brought Andy Sassine around $107,600.

According to the SEC Form 4 filings, Andy Sassine has made a total of 0 transactions in NeuroBo Pharmaceuticals Inc (NRBO) over the past 5 years. The most-recent trade in NeuroBo Pharmaceuticals Inc is the acquisition of 4 shares on March 10, 2017, which cost Andy Sassine around $199,997.

Insider Trading History of Andy Sassine

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Andy Sassine Trading Performance

GuruFocus tracks the stock performance after each of Andy Sassine's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Andy Sassine is 34.62%. GuruFocus also compares Andy Sassine's trading performance to market benchmark return within the same time period. The performance of stocks bought by Andy Sassine within 3 months outperforms 4 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Andy Sassine's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Andy Sassine

Average Return

Average return per transaction

Outperforming Transactions

4 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 21.86
Relative Return to S&P 500(%) 19.34

Andy Sassine Ownership Network

Ownership Network List of Andy Sassine

No Data

Ownership Network Relation of Andy Sassine


Andy Sassine Owned Company Details

What does icad Inc do?

Who are the key executives at icad Inc?

Andy Sassine is the director of icad Inc. Other key executives at icad Inc include See Remarks Eric Lonnqvist , See Remarks Daniel Joseph Shea , and Sr. VP of R&D Jonathan Go .

icad Inc (ICAD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of icad Inc (ICAD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of icad Inc (ICAD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

icad Inc (ICAD)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

icad Inc Insider Transactions

No Available Data

Andy Sassine Mailing Address

Above is the net worth, insider trading, and ownership report for Andy Sassine. You might contact Andy Sassine via mailing address: 82 Devonshire Street, Boston Ma 02109.

Discussions on Andy Sassine

No discussions yet.